Biological
Autologous CAR-T cells
Autologous CAR-T cells is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Terminated(1)
Other(1)
Detailed Status
unknown1
Withdrawn1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
unknown133%
withdrawn133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
withdrawnphase_1
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
NCT05513612
recruitingphase_1
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
NCT05528887
unknownphase_1
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
NCT03312205
Clinical Trials (3)
Showing 3 of 3 trials
NCT05513612Phase 1
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
NCT05528887Phase 1
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
NCT03312205Phase 1
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3